Drug Approval | September 03, 2021
Covid-19 vaccine clinical trial for people with autoimmune disease
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
This is Enzene Biosciences third biosimilar to be approved
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
This is the first of its kind vaccine for Covid 19 to get the go-ahead
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Subscribe To Our Newsletter & Stay Updated
